RT Journal Article SR Electronic T1 Off-Label Use of Drugs and Devices in the Neuroendovascular Suite JF American Journal of Neuroradiology JO Am. J. Neuroradiol. FD American Society of Neuroradiology DO 10.3174/ajnr.A3447 A1 M.M. Abdihalim A1 A.E. Hassan A1 A.I. Qureshi YR 2013 UL http://www.ajnr.org/content/early/2013/03/21/ajnr.A3447.abstract AB SUMMARY: The off-label use of drugs and devices in neuroendovascular procedures is common. Neurointerventionalists should be well aware of the level of evidence available in support of the off-label use of drugs and devices in their practice and some of the potential adverse events associated with them. These uses are categorized as I or II if they have been evaluated as primary or ancillary interventions in prospective trials/registries of neuroendovascular procedures and III if they were evaluated in case series. Category IV use is based on evaluation as primary or ancillary interventions in prospective trials/registries of non-neuroendovascular procedures. Physicians are allowed to use off-label drugs and procedures if there is strong evidence that they are beneficial for the patient. The neurointerventional professional societies agree that off-label use of drugs and devices is an important part of the specialty, but practicing providers should base their decisions on sound evidence when using such drugs and devices. Abbreviations GDCGuglielmi detachable coilIAintra-arterialICHintracerebral hemorrhagePROACTProlyse in Acute Cerebral ThromboembolismUKurokinase